Sökning: id:"swepub:oai:gup.ub.gu.se/64948" >
Rofecoxib in the ac...
Rofecoxib in the acute treatment of migraine: a randomized controlled clinical trial
-
Saper, Joel (författare)
-
- Dahlöf, Carl, 1947 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation
-
So, Y. (författare)
-
visa fler...
-
Tfelt-Hansen, Peer (författare)
-
Malbecq, W. (författare)
-
Loeys, T. (författare)
-
Barraclough, E. (författare)
-
Klipfel, M. (författare)
-
Lines, Christoffer (författare)
-
Visser, Hester (författare)
-
Reines, S. (författare)
-
Yuen, E. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2006
- 2006
- Engelska.
-
Ingår i: Headache. ; 46:2, s. 264-75
- Relaterad länk:
-
https://gup.ub.gu.se...
Abstract
Ämnesord
Stäng
- OBJECTIVE: To investigate the efficacy, tolerability, and safety of rofecoxib and ibuprofen for acute migraine treatment. BACKGROUND: Rofecoxib was effective and well tolerated in a previous study of treatment of a single migraine attack. We sought to replicate these findings for a single attack and also study the clinical profile of rofecoxib in the acute treatment of multiple migraine attacks. Ibuprofen was included as a reference nonselective NSAID. METHODS: Adult migraineurs (n = 783) treated one migraine attack with either rofecoxib (25 or 50 mg), ibuprofen 400 mg, or placebo in a randomized, double-blind study. Patients could elect to enroll in a 3-month double-blind extension phase. RESULTS: In the single-attack phase, headache relief at 2 hours postdose was reported by 59.4%, 62.2%, and 57.7% of patients who took rofecoxib 25 mg, rofecoxib 50 mg, and ibuprofen 400 mg, respectively, versus 30.5% for placebo (all P < .001 vs placebo). The active drugs were statistically superior to placebo on a variety of additional measures. In the extension phase, the mean percentage of patients' attacks with headache relief at 2 hours postdose was 61.8% for rofecoxib 25 mg, 65.4% for rofecoxib 50 mg, and 59.3% for ibuprofen 400 mg. The mean percentage of patients' attacks with 24-hour sustained headache relief was greater for rofecoxib 50 mg (52.0%) than for rofecoxib 25 mg (47.8%, P < .050) or ibuprofen (39.0%, P < .010). In the single-attack phase, the adverse event rate was higher for rofecoxib 50 mg (37.8%) than placebo (27.8%, P < .050); rates were similar to placebo for rofecoxib 25 mg (32.0%, n.s.) and ibuprofen 400 mg (28.1%, n.s.). In the extension phase, treatment groups had similar adverse event rates. CONCLUSIONS: Rofecoxib 25 and 50 mg and ibuprofen 400 mg were effective and generally well tolerated in the acute treatment of migraine.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Fysiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Physiology (hsv//eng)
Nyckelord
- Acute Disease
- Adult
- Anti-Inflammatory Agents
- Non-Steroidal/ therapeutic use
- Dizziness/chemically induced
- Dose-Response Relationship
- Drug
- Double-Blind Method
- Female
- Humans
- Ibuprofen/ therapeutic use
- Lactones/ therapeutic use
- Male
- Middle Aged
- Migraine Disorders/ drug therapy
- Nausea/chemically induced
- Serotonin Agonists/ therapeutic use
- Sulfones/ therapeutic use
- Treatment Outcome
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Saper, Joel
-
Dahlöf, Carl, 19 ...
-
So, Y.
-
Tfelt-Hansen, Pe ...
-
Malbecq, W.
-
Loeys, T.
-
visa fler...
-
Barraclough, E.
-
Klipfel, M.
-
Lines, Christoff ...
-
Visser, Hester
-
Reines, S.
-
Yuen, E.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Fysiologi
- Artiklar i publikationen
- Headache
- Av lärosätet
-
Göteborgs universitet